8-K
filed January 27, 2026, 6:59 PM ET
ticker DHTI
CIK 0000725394
debt
confidence high
sentiment neutral
materiality 0.65
Dalrada Technology Group, Inc. (DHTI): debt financing — Dalrada subsidiary Genefic enters $20M guarantee & $5M credit facility; CEO personally guarantees
Dalrada Technology Group, Inc.
- Genefic Inc. entered SBLC Agreement with IBS Equity Fund III for up to $20M in guarantees and related ARL Agreement for up to $5M revolving credit.
- CEO Brian Bonar provides unlimited personal guaranty for Genefic's obligations; board acknowledges potential conflicts of interest.
- Company pledges 100% equity interests in all subsidiaries and grants first-priority security interest in substantially all assets.
- Fees include $140,000 cash at closing, $165,000 promissory note (24-month $7,652 monthly), and $225,000 warrant for 5% of Genefic membership units.
- Availability period Dec 31, 2025 to Dec 31, 2030; default triggers include failure to maintain 25% collateral value and cross-defaults.
Key facts
Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Dalrada Technology Group, Inc. incurred guarantee of $20,000,000 with IBS Equity Fund III, LLC at default rate maturing December 31, 2030.
- Instrument
- guarantee
- Principal
- $20,000,000
- Counterparty
- IBS Equity Fund III, LLC
- Rate
- default rate
- Maturity
- December 31, 2030
- Event
- incurrence
Exact text from the filing
for the issuance of various guarantees, including standby letters of credit, equity commitment letters, and other financial instruments, up to an aggregate commitment amount of $20,000,000. The SBLC Agreement supports a related Credit, Security, and Account Purchase Agreement (the "ARL Agreement") dated the same day, under which the Secured Party (or its
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Dalrada Technology Group, Inc. entered into Master Performance Standby Letter of Credit and Guaranty Agreement with IBS Equity Fund III, LLC valued at $20,000,000 (effective 2025-12-31).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- IBS Equity Fund III, LLC
- Value
- $20,000,000
- Effective
- 2025-12-31
Exact text from the filing
On January 21, 2026, Genefic Inc. ("Genefic"), a wholly-owned subsidiary of Dalrada Technology Group, Inc. (the "Company"), entered into a Master Performance Standby Letter of Credit and Guaranty Agreement dated December 31, 2025 (the "SBLC Agreement") with IBS Equity Fund III, LLC, a division of IBS Investment Bank (the "Secured Party"). The SBLC Agreement provides for the issuance of various guarantees, including standby letters of credit, equity commitment letters, and other financial instruments, up to an aggregate commitment amount of $20,000,000.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Dalrada Technology Group, Inc. entered into Credit, Security, and Account Purchase Agreement with IBS Equity Fund III, LLC valued at $5,000,000 (effective 2025-12-31).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- IBS Equity Fund III, LLC
- Value
- $5,000,000
- Effective
- 2025-12-31
Exact text from the filing
The SBLC Agreement supports a related Credit, Security, and Account Purchase Agreement (the "ARL Agreement") dated the same day, under which the Secured Party (or its affiliate, IBS Private Credit Fund IV, LLC) may extend revolving credit through the purchase of accounts receivable on behalf of Genefic for the benefit of third-party beneficiaries in connection with Genefic's business operations, up to $5,000,000.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.